• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤浸润淋巴细胞对导管原位癌的预后及预测意义

Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ.

作者信息

Xu Fei-Fei, Zheng Sai-Fang, Xu Cheng, Cai Gang, Wang Shu-Bei, Qi Wei-Xiang, Wang Chao-Fu, Chen Jia-Yi, Lu Cao

机构信息

Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Department of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

出版信息

Oncoimmunology. 2021 Mar 18;10(1):1875637. doi: 10.1080/2162402X.2021.1875637.

DOI:10.1080/2162402X.2021.1875637
PMID:33796401
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7993193/
Abstract

This study aims to identify the density of TILs in ductal carcinoma in situ (DCIS) in terms of prognostic significance with recurrence and the benefit of whole breast irradiation (WBI). The clinicopathological data of DCIS patients from Jan 2009 to Dec 2016 who received breast-conserving surgery (BCS) were retrospectively reviewed. Cox regression analysis was used to confirm independent prognostic factors of ipsilateral breast tumor recurrence (IBTR). Kaplan-Meier method was utilized to analyze IBTR and values of WBI. Touching-tumor-infiltrating lymphocytes (TILs) were defined by TILs touching or within one lymphocyte cell thickness from the malignant ducts' basement membrane. In total, 129 patients were enrolled in this analysis with 98 patients who received WBI. After a median follow-up of 53.0 months, there were 16 IBTR events with five invasive IBTRs. Univariate and multivariate analyses showed that touching-TILs >5 were an independent prognostic factor for higher IBTR (HR = 6.17, 95%CI 1.95-19.56, < .01). The whole cohort was classified into two subgroups: dense group (>5 touching-TILs per duct) and sparse group (≤5 touching-TILs per duct). Dense touching-TILs were associated with unfavorable biologic characteristics. The 5-y rate of IBTR between dense and sparse group was 29.0% versus 4.5% ( < .01). For the sparse group, WBI significantly reduced the rate of 5-y-IBTR risk from 13.2% to 1.7% ( = .02), but there was no benefit of WBI in the dense group. Touching-TILs density was heterogeneous in patients with DCIS. Sparse touching-TILs were associated with better prognosis and benefit from WBI. Dense touching-TILs not only were associated with a higher risk of IBTR but also lack of benefit from WBI.

摘要

本研究旨在确定导管原位癌(DCIS)中肿瘤浸润淋巴细胞(TILs)的密度对于复发的预后意义以及全乳照射(WBI)的益处。回顾性分析了2009年1月至2016年12月期间接受保乳手术(BCS)的DCIS患者的临床病理资料。采用Cox回归分析确定同侧乳腺肿瘤复发(IBTR)的独立预后因素。利用Kaplan-Meier法分析IBTR和WBI的价值。接触肿瘤浸润淋巴细胞(TILs)定义为TILs接触或距恶性导管基底膜一个淋巴细胞厚度范围内。本分析共纳入129例患者,其中98例接受了WBI。中位随访53.0个月后,发生16例IBTR事件,其中5例为浸润性IBTR。单因素和多因素分析显示,接触TILs>5是IBTR升高的独立预后因素(HR = 6.17,95%CI 1.95 - 19.56,P <.01)。整个队列分为两个亚组:密集组(每个导管>5个接触TILs)和稀疏组(每个导管≤5个接触TILs)。密集的接触TILs与不良生物学特征相关。密集组和稀疏组的5年IBTR率分别为29.0%和4.5%(P <.01)。对于稀疏组,WBI显著降低了5年IBTR风险率,从13.2%降至1.7%(P =.02),但在密集组中WBI没有益处。DCIS患者的接触TILs密度存在异质性。稀疏的接触TILs与较好的预后相关且受益于WBI。密集的接触TILs不仅与较高的IBTR风险相关,而且未从WBI中获益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6453/7993193/aef55f2c47d2/KONI_A_1875637_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6453/7993193/ba6bdee82745/KONI_A_1875637_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6453/7993193/788573157ffe/KONI_A_1875637_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6453/7993193/68ab4fcde8b6/KONI_A_1875637_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6453/7993193/aef55f2c47d2/KONI_A_1875637_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6453/7993193/ba6bdee82745/KONI_A_1875637_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6453/7993193/788573157ffe/KONI_A_1875637_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6453/7993193/68ab4fcde8b6/KONI_A_1875637_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6453/7993193/aef55f2c47d2/KONI_A_1875637_F0004_OC.jpg

相似文献

1
Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ.肿瘤浸润淋巴细胞对导管原位癌的预后及预测意义
Oncoimmunology. 2021 Mar 18;10(1):1875637. doi: 10.1080/2162402X.2021.1875637.
2
Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS).肿瘤浸润淋巴细胞在当代女性导管原位癌(DCIS)队列中的作用。
Ann Surg Oncol. 2019 Oct;26(10):3337-3343. doi: 10.1245/s10434-019-07562-x. Epub 2019 Jun 25.
3
Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast.肿瘤浸润淋巴细胞对乳腺导管原位癌的预后意义。
Mod Pathol. 2018 Aug;31(8):1226-1236. doi: 10.1038/s41379-018-0040-8. Epub 2018 Mar 20.
4
Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.保乳手术后原位导管癌与浸润性乳腺癌同侧乳腺肿瘤复发情况的比较。
World J Surg Oncol. 2016 Apr 27;14:126. doi: 10.1186/s12957-016-0885-6.
5
Touching tumour-infiltrating lymphocytes in low-risk ductal carcinoma in situ (DCIS) correlate with upgrading to high-grade DCIS.低危型乳腺导管原位癌(DCIS)中浸润淋巴细胞的检出与向高级别 DCIS 升级相关。
Histopathology. 2022 Jan;80(2):291-303. doi: 10.1111/his.14539. Epub 2021 Sep 22.
6
Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.EORTC boost 与非 boost 试验长期随访后乳腺癌局部控制的预后因素:一项随机临床试验。
JAMA Oncol. 2017 Jan 1;3(1):42-48. doi: 10.1001/jamaoncol.2016.3031.
7
Tumour-infiltrating lymphocytes in ductal carcinoma in situ (DCIS)-assessment with three different methodologies and correlation with Oncotype DX DCIS Score.导管原位癌(DCIS)中浸润淋巴细胞的评估——三种不同方法学的评估及与 Oncotype DX DCIS 评分的相关性。
Histopathology. 2020 Nov;77(5):749-759. doi: 10.1111/his.14181. Epub 2020 Sep 26.
8
Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery.保乳手术治疗乳腺导管原位癌患者的临床病理特征的预后意义。
Clin Breast Cancer. 2018 Dec;18(6):441-450.e2. doi: 10.1016/j.clbc.2018.04.002. Epub 2018 Apr 10.
9
Evaluation of tumor infiltrating lymphocytes as a prognostic biomarker in patients with ductal carcinoma in situ of the breast.评估肿瘤浸润淋巴细胞作为乳腺导管原位癌患者的预后生物标志物。
Breast Cancer Res Treat. 2024 Nov;208(1):9-18. doi: 10.1007/s10549-024-07466-9. Epub 2024 Aug 24.
10
Prognostic value of tumor-infiltrating lymphocytes in DCIS: a meta-analysis.肿瘤浸润淋巴细胞在 DCIS 中的预后价值:一项荟萃分析。
BMC Cancer. 2022 Jul 18;22(1):782. doi: 10.1186/s12885-022-09883-9.

引用本文的文献

1
Decoding tumor-infiltrating lymphocytes heterogeneity in ductal carcinoma in situ: immune microenvironment dynamics and prognostic insights.解码导管原位癌中肿瘤浸润淋巴细胞的异质性:免疫微环境动态及预后见解
Discov Oncol. 2025 Jul 28;16(1):1435. doi: 10.1007/s12672-025-03288-3.
2
From ductal carcinoma in situ to invasive breast cancer: the prognostic value of the extracellular microenvironment.从导管原位癌到浸润性乳腺癌:细胞外微环境的预后价值
J Exp Clin Cancer Res. 2024 Dec 23;43(1):329. doi: 10.1186/s13046-024-03236-z.
3
Profiling of Tumour-Infiltrating Lymphocytes and Tumour-Associated Macrophages in Ovarian Epithelial Cancer-Relation to Tumour Characteristics and Impact on Prognosis.

本文引用的文献

1
Tumour-infiltrating lymphocytes in ductal carcinoma in situ (DCIS)-assessment with three different methodologies and correlation with Oncotype DX DCIS Score.导管原位癌(DCIS)中浸润淋巴细胞的评估——三种不同方法学的评估及与 Oncotype DX DCIS 评分的相关性。
Histopathology. 2020 Nov;77(5):749-759. doi: 10.1111/his.14181. Epub 2020 Sep 26.
2
Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.导管原位癌的免疫微环境:与乳腺浸润性癌的比较。
Breast Cancer Res. 2020 Mar 26;22(1):32. doi: 10.1186/s13058-020-01267-w.
3
The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
卵巢上皮癌中肿瘤浸润淋巴细胞和肿瘤相关巨噬细胞的分析——与肿瘤特征的关系及对预后的影响
Int J Mol Sci. 2024 Apr 20;25(8):4524. doi: 10.3390/ijms25084524.
4
Identifying recurrences and metastasis after ductal carcinoma in situ (DCIS) of the breast.乳腺癌导管原位癌(DCIS)术后复发和转移的检测。
Histopathology. 2023 Jan;82(1):106-118. doi: 10.1111/his.14804.
5
A Novel Nomogram for Predicting Prognosis and Tailoring Local Therapy Decision for Ductal Carcinoma In Situ after Breast Conserving Surgery.一种用于预测保乳手术后导管原位癌预后及制定局部治疗决策的新型列线图
J Clin Med. 2022 Sep 1;11(17):5188. doi: 10.3390/jcm11175188.
6
Prognostic value of tumor-infiltrating lymphocytes in DCIS: a meta-analysis.肿瘤浸润淋巴细胞在 DCIS 中的预后价值:一项荟萃分析。
BMC Cancer. 2022 Jul 18;22(1):782. doi: 10.1186/s12885-022-09883-9.
7
Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast.乳腺导管原位癌(DCIS)及微浸润性导管原位癌(DCIS-Mi)中肿瘤浸润淋巴细胞(TILs)的临床病理特征及预后分析。
Breast Cancer Res Treat. 2022 May;193(1):111-120. doi: 10.1007/s10549-022-06553-z. Epub 2022 Mar 8.
乳腺导管原位癌中免疫微环境的预后意义。
Br J Cancer. 2020 May;122(10):1496-1506. doi: 10.1038/s41416-020-0797-7. Epub 2020 Mar 17.
4
Higher densities of tumour-infiltrating lymphocytes and CD4 T cells predict recurrence and progression of ductal carcinoma in situ of the breast.肿瘤浸润淋巴细胞和 CD4 T 细胞密度较高,预示着乳腺导管原位癌的复发和进展。
Histopathology. 2020 May;76(6):852-864. doi: 10.1111/his.14055.
5
Breast cancer statistics, 2019.乳腺癌统计数据,2019 年。
CA Cancer J Clin. 2019 Nov;69(6):438-451. doi: 10.3322/caac.21583. Epub 2019 Oct 2.
6
Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS).肿瘤浸润淋巴细胞在当代女性导管原位癌(DCIS)队列中的作用。
Ann Surg Oncol. 2019 Oct;26(10):3337-3343. doi: 10.1245/s10434-019-07562-x. Epub 2019 Jun 25.
7
Prognostic role of immune infiltrates in breast ductal carcinoma in situ.免疫浸润在乳腺导管原位癌中的预后作用。
Breast Cancer Res Treat. 2019 Aug;177(1):17-27. doi: 10.1007/s10549-019-05272-2. Epub 2019 May 27.
8
Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial.保乳手术后放疗的效果取决于肿瘤浸润淋巴细胞的存在:SweBCG91RT 随机试验的长期随访结果。
J Clin Oncol. 2019 May 10;37(14):1179-1187. doi: 10.1200/JCO.18.02157. Epub 2019 Apr 2.
9
Coexistence of regulatory B cells and regulatory T cells in tumor-infiltrating lymphocyte aggregates is a prognostic factor in patients with breast cancer.肿瘤浸润淋巴细胞聚集中调节性 B 细胞和调节性 T 细胞共存是乳腺癌患者的预后因素。
Breast Cancer. 2019 Mar;26(2):180-189. doi: 10.1007/s12282-018-0910-4. Epub 2018 Sep 22.
10
Breaking through to the Other Side: Microenvironment Contributions to DCIS Initiation and Progression.突破到另一侧:微环境对导管原位癌起始和进展的作用
J Mammary Gland Biol Neoplasia. 2018 Dec;23(4):207-221. doi: 10.1007/s10911-018-9409-z. Epub 2018 Aug 31.